A global leader in cancer treatment
Sirtex Medical is a global healthcare business with offices in the US, Australia, Germany and Singapore, working to improve outcomes in people with cancer.
Our current lead product is a targeted radiation therapy for liver tumours called SIR-Spheres® Y-90 resin microspheres. More than 100,000 doses have been supplied to treat patients with liver cancer at more than 1,300 medical centres in over 50 countries.
What are SIR-Spheres® Y-90 resin microspheres and how are they used?
SIR-Spheres® Y-90 resin microspheres is a prescription device for the treatment of inoperable liver tumours. It is a minimally invasive treatment that delivers high doses of high-energy beta radiation directly to the tumours.
This therapy is called Selective Internal Radiation Therapy (SIRT) and is performed using minimally invasive surgical techniques by an interventional radiologist.
By using the tumors’ blood supply, the microspheres selectively target liver tumours with a dose of radiation that is up to 40 times higher than conventional radiotherapy, while sparing healthy tissue.
In the United States, SIR-Spheres® Y-90 resin microspheres received Premarket Approval (PMA) from the FDA and are indicated for the treatment of non-resectable metastatic liver tumours from primary colorectal cancer in combination with intrahepatic artery chemotherapy using floxuridine.
SIR-Spheres® Y-90 resin microspheres are approved for the treatment of inoperable liver tumours in Australia, the European Union, Argentina, Brazil, Canada and several countries in Asia, such as India and Singapore.